DNA Topoisomerases, Type II
"DNA Topoisomerases, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex.
| Descriptor ID |
D004250
|
| MeSH Number(s) |
D08.811.399.403.741
|
| Concept/Terms |
DNA Topoisomerases, Type II- DNA Topoisomerases, Type II
- Type II DNA Topoisomerase
- Topoisomerase II
- DNA Topoisomerase (ATP-Hydrolysing)
- DNA Topoisomerase II
- DNA Type 2 Topoisomerase
|
Below are MeSH descriptors whose meaning is more general than "DNA Topoisomerases, Type II".
Below are MeSH descriptors whose meaning is more specific than "DNA Topoisomerases, Type II".
This graph shows the total number of publications written about "DNA Topoisomerases, Type II" by people in this website by year, and whether "DNA Topoisomerases, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 3 | 0 | 3 |
| 1996 | 3 | 2 | 5 |
| 1997 | 3 | 1 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 3 | 1 | 4 |
| 2000 | 0 | 2 | 2 |
| 2001 | 3 | 4 | 7 |
| 2002 | 1 | 3 | 4 |
| 2003 | 0 | 2 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 6 | 2 | 8 |
| 2006 | 3 | 3 | 6 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 2 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Topoisomerases, Type II" by people in Profiles.
-
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Semin Oncol. 2019 12; 46(6):397-402.
-
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018 05 15; 9(1):1908.
-
Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia. 2018 03; 32(3):663-674.
-
Looping-out mechanism for resolution of replicative stress at telomeres. EMBO Rep. 2017 08; 18(8):1412-1428.
-
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther. 2015; 16(12):1726-37.
-
Regulation of sister chromosome cohesion by the replication fork tracking protein SeqA. PLoS Genet. 2013; 9(8):e1003673.
-
A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. Breast Cancer Res Treat. 2013 Apr; 138(3):691-8.
-
Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs. Cancer Res. 2013 Jan 15; 73(2):1000-10.
-
The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae. Mol Pharmacol. 2013 Jan; 83(1):225-34.
-
Coordinated effects of microRNA-494 induce G2/M arrest in human cholangiocarcinoma. Cell Cycle. 2012 Jul 15; 11(14):2729-38.